Revolution Medicines (RVMD) Operating Leases (2020 - 2026)
Revolution Medicines (RVMD) posted quarterly Operating Leases of $140.0 million for Q1 2026, up 15.37% year-over-year from $121.4 million in Q1 2025, and down 1.56% quarter-over-quarter from $142.2 million in Q4 2025.
Revolution Medicines (RVMD) Operating Leases (2020 - 2026) Analysis & Trends
Revolution Medicines' Operating Leases history runs 7 years deep, the most recent figure standing at $140.0 million for Q1 2026.
- In Q1 2026, Operating Leases rose 15.37% year-over-year to $140.0 million; the TTM figure through Mar 2026 stood at $140.0 million (up 15.37% YoY), while the FY2025 annual figure was $142.2 million, up 15.66% from the prior year.
- Operating Leases for Q1 2026 stood at $140.0 million, down from $142.2 million in the prior quarter.
- The five-year high for Operating Leases was $142.2 million in Q4 2025, with the low at $57.1 million in Q3 2023.
- The 5-year median for Operating Leases is $79.1 million (2024), against an average of $89.0 million.
- Peak annual rise in Operating Leases reached 116.88% in 2022, while the deepest fall reached 4.94% in 2022.
- Revolution Medicines' Operating Leases stood at $57.4 million in 2022, then jumped by 40.3% to $80.6 million in 2023, then jumped by 52.62% to $123.0 million in 2024, then climbed by 15.66% to $142.2 million in 2025, then retreated by 1.56% to $140.0 million in 2026.
- Business Quant data shows RVMD's Operating Leases at $140.0 million in Q1 2026, $142.2 million in Q4 2025, and $142.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 137.74 Mn |
| Mar 31, 2026 | 140.02 Mn |
| Dec 31, 2025 | 142.23 Mn |
| Sep 30, 2025 | 142.14 Mn |
| Jun 30, 2025 | 119.70 Mn |
| Mar 31, 2025 | 121.36 Mn |
| Dec 31, 2024 | 122.97 Mn |
| Sep 30, 2024 | 78.31 Mn |
| Jun 30, 2024 | 79.08 Mn |
| Mar 31, 2024 | 79.86 Mn |
| Dec 31, 2023 | 80.58 Mn |
| Sep 30, 2023 | 57.09 Mn |
| Jun 30, 2023 | 57.54 Mn |
| Mar 31, 2023 | 57.68 Mn |
| Dec 31, 2022 | 57.43 Mn |
| Sep 30, 2022 | 58.18 Mn |
| Jun 30, 2022 | 58.92 Mn |
| Mar 31, 2022 | 59.58 Mn |
| Dec 31, 2021 | 60.42 Mn |
| Sep 30, 2021 | 26.83 Mn |